FILING ANALYSIS · MONDAY, NOVEMBER 9
Whitehawk Therapeutics, Inc. WHWK — 8-K: Results of Operations and Financial Condition
neutral
The company reported a net loss of $21.2 million for the quarter ended September 30, 2026, and cash, cash equivalents, and short-term investments of $169.7 million, anticipated to fund operations into 2H 2028. No significant quantified surprises were disclosed in the filing.
How we read impact: we grade every directional call in the open. Impact labels are AI estimates — not investment advice. See the full disclaimer.
Get filings like this every market day
The US SEC filings, UK RNS, EU notices, and Polymarket odds that matter — scored by AI, in one email.
Subscribe free →